Publications

  1. Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Hart SN, Cheville JC, Parker AS. Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. Carcinogenesis. 2014 Apr; 35(4):822-7. Epub 2013 Dec 28.
    View PubMed
  2. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166(1):15-23. Epub 2014 Mar 10.
    View PubMed
  3. Hutchinson R, Parker AS, Arnold M, Bowers SP, Haley WE, Diehl N, Stone R, Lynch SA, Smith CD, Thiel DD. Prospective evaluation of 24-hour urine profiles following bariatric surgery in a modern comprehensive care bariatric clinic. Clin Nephrol. 2014 Feb 05.
    View PubMed
  4. Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC, Parker AS. ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. BMC Urol. 2014; 14:14. Epub 2014 Jan 31.
    View PubMed
  5. Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer. 2014 Apr 1; 120(7):1059-67. Epub 2013 Dec 30.
    View PubMed
  6. Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC. Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. Eur Urol. 2013 Dec 25.
    View PubMed
  7. Parker AS, Arnold ML, Diehl ND, Hassan L, Thiel DD. Evaluation of awareness of risk factors for kidney cancer among patients presenting to a urology clinic. Scand J Urol. 2013 Dec 12. [Epub ahead of print]
    View PubMed
  8. Arnold ML, Thiel DD, Diehl N, Wu KJ, Ames S, Parker AS. Comparison of baseline quality of life measures between renal cell carcinoma patients undergoing partial versus radical nephrectomy. BMC Urol. 2013; 13:52. Epub 2013 Oct 22.
    View PubMed
  9. Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ. Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer. J Radiat Oncol. 2013 Sep 1; 2(3):309-14.
    View PubMed
  10. Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, Diehl N, Karnes RJ. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):352-6. Epub 2013 Aug 20.
    View PubMed
  11. Thiel DD, Jorns J, Lohse CM, Cheville JC, Thompson RH, Parker AS. Maximum tumor diameter is not an accurate predictor of renal cell carcinoma tumor volume. Scand J Urol. 2013 Dec; 47(6):472-5. Epub 2013 Jul 24.
    View PubMed
  12. Tyson MD, Humphreys MR, Castle EP, Parker AS. Reply. Urology. 2013 Jul; 82(1):47. Epub 2013 May 22.
    View PubMed
  13. Tyson MD, Humphreys MR, Parker AS, Thiel DD, Joseph RW, Andrews PE, Castle EP. Age-period-cohort analysis of renal cell carcinoma in United States adults. Urology. 2013 Jul; 82(1):43-7. Epub 2013 May 22.
    View PubMed
  14. Peterson JL, Buskirk SJ, Heckman MG, Parker AS, Diehl NN, Tzou KS, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Pisansky TM. Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer. ISRN Oncol. 2013; 2013:239241. Epub 2013 Mar 31.
    View PubMed
  15. McDonnell SK, Riska SM, Klee EW, Thorland EC, Kay NE, Thibodeau SN, Parker AS, Eckel-Passow JE. Experimental designs for array comparative genomic hybridization technology. Cytogenet Genome Res. 2013; 139(4):250-7. Epub 2013 Mar 27.
    View PubMed
  16. Mmeje CO, Martin AD, Nunez-Nateras R, Parker AS, Thiel DD, Castle EP. Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. Curr Urol Rep. 2013 Feb; 14(1):26-31.
    View PubMed
  17. McLaughlin SA, Bagaria S, Gibson T, Arnold M, Diehl N, Crook J, Parker A, Nguyen J. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2013 Mar; 216(3):380-9; quiz 511-3. Epub 2012 Dec 21.
    View PubMed
  18. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012 Nov-Dec; 35(9):711-5.
    View PubMed
  19. Jepperson MA, Thiel DD, Cernigliaro JG, Broderick GA, Parker AS, Haley WE. Determination of ureter stent appearance on dual-energy computed tomography scan. Urology. 2012 Nov; 80(5):986-9. Epub 2012 Aug 22.
    View PubMed
  20. Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, Broderick GA, Parker AS. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology. 2013 Jun; 22(6):1328-35. Epub 2012 Aug 01.
    View PubMed
  21. Jorns JJ, Thiel DD, Lohse C, Williams A, Arnold M, Cheville J, Leibovich B, Parker AS. Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinoma. Urology. 2012 Jul; 80(1):147-50.
    View PubMed
  22. Petrou SP, Rogers AE, Parker AS, Green KM, McRoberts JW. Dorsal vaginal graft urethroplasty for female urethral stricture disease. BJU Int. 2012 Dec; 110(11 Pt C):E1090-5. Epub 2012 May 17.
    View PubMed
  23. Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate. 2012 Dec 1; 72(16):1757-66. Epub 2012 Apr 18.
    View PubMed
  24. Hutchinson RC, Thiel DD, Tavlarides AM, Diehl NN, Parker AS. The effect of robot-assisted laparoscopic prostatectomy on nocturia. J Endourol. 2012 Jul; 26(7):861-5. Epub 2012 Apr 17.
    View PubMed
  25. Thiel DD, Lohse CM, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus? Int Urol Nephrol. 2012 Aug; 44(4):1005-12. Epub 2012 Apr 13.
    View PubMed
  26. Thiel DD, Hutchinson R, Diehl N, Tavlarides A, Williams A, Parker AS. Impact of fellowship training on one-year outcomes of robotic-assisted prostatectomy. JSLS. 2012 Apr-Jun; 16(2):195-201.
    View PubMed
  27. Adkisson CD, Bagaria SP, Parker AS, Bray JM, Gibson T, Thomas CS, Heckman MG, McLaughlin SA. Which eligible breast conservation patients choose mastectomy in the setting of newly diagnosed breast cancer? Ann Surg Oncol. 2012 Apr; 19(4):1129-36.
    View PubMed
  28. Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int. 2012 Oct; 110(7):956-60. Epub 2012 Feb 02.
    View PubMed
  29. Bot BM, Eckel-Passow JE, LeGrand SN, Hilton T, Cheville JC, Igel T, Parker AS. Expression of endothelin 2 and localized clear cell renal cell carcinoma. Hum Pathol. 2012 Jun; 43(6):843-9. Epub 2011 Nov 01.
    View PubMed
  30. Thiel DD, Brisson TE, Heckman MG, Arnold M, Haley W, Khambhati J, Wehle MJ, Igel TC, Parker AS. Evaluation of pancreatic damage after extracorporeal shock wave lithotripsy, percutaneous stone surgery, and ureteroscopy. Urology. 2011 Jun; 77(6):1288-91. Epub 2011 Jan 07.
    View PubMed
  31. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011; 29(6):593-605.
    View PubMed
  32. Thiel DD, Brisson TE, Heckman MG, Arnold M, Haley WE, Khambhati J, Wehle MJ, Igel TC, Parker AS. Evaluation of pancreatic damage after extracorporeal shock wave lithotripsy, percutaneous stone surgery, and ureteroscopy. J Endourol. 2011; 25(11):1690-1.
  33. Leroy TJ, Thiel DD, Duchene DA, Parker AS, Igel TC, Wehle MJ, Goetzl M, Thrasher JB. Safety and peri-operative outcomes during learning curve of robot-assisted laparoscopic prostatectomy: a multi-institutional study of fellowship-trained robotic surgeons versus experienced open radical prostatectomy surgeons incorporating robot-assisted laparoscopic prostatectomy. J Endourol. 2010 Oct; 24(10):1665-9.
    View PubMed
  34. Jacobson DJ, St Sauver JL, Parker AS, McGree ME, Sarma AV, Girman CJ, Lieber MM, Jacobsen SJ. Estimation of prostate size in community-dwelling men. Urology. 2011 Feb; 77(2):422-6. Epub 2010 Aug 30.
    View PubMed
  35. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  36. Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc. 2009 Aug; 84(8):702-6.
    View PubMed
  37. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Dec 1; 75(5):1364-70. Epub 2009 May 21.
    View PubMed
  38. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15; 115(10):2092-103.
    View PubMed
  39. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):444-53. Epub 2009 Feb 03.
    View PubMed
  40. Feldstein MS, Rhodes DJ, Parker AS, Orford RR, Castle EP. The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int. 2009 Jul; 104(1):53-6. Epub 2009 Jan 12.
    View PubMed
  41. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA, Anastasiadis PZ. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem. 2008 Jun 27; 283(26):18344-54. Epub 2008 Apr 11.
    View PubMed
  42. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol. 2008 Aug; 39(8):1176-84. Epub 2008 Jun 05.
    View PubMed
  43. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008 Apr 1; 112(7):1471-9.
    View PubMed
  44. Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol. 2008 Apr; 15(4):304-8.
    View PubMed
  45. Parker AS, Lewis R, Heckman MG, Diehl NH, Brisson T, Pak R, Wehle MJ. Evaluation of the impact of body mass index on outcome among renal mass patients treated with hand-assisted laparoscopic radical nephrectomy. J Endourol. 2008 Feb; 22(2):301-6.
    View PubMed
  46. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenheim JL, Gile GG, Giovannucci E, Horn-Ross PL, Leitzmann M, Marshall JR, Mannisto S, McCullough ML, Miller AB, Parker AS, Pietinen P, Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer. 2007 Nov 15; 121(10):2246-53.
    View PubMed
  47. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007 Aug 15; 13(16):4740-9.
    View PubMed
  48. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, Folsom AR, Freudenheim JL, Giovannucci E, Graham S, Horn-Ross PL, Leitzmann MF, McCullough ML, Miller AB, Parker AS, Rodriguez C, Rohan TE, Schatzkin A Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007 May 16; 99(10):801-10.
    View PubMed
  49. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1749-56.
    View PubMed
  50. Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol. 2007 Mar; 38(3):453-61. Epub 2006 Dec 22.
    View PubMed
  51. Tarpey P, Thomas S, Sarvananthan N, Mallya U, Lisgo S, Talbot CJ, Roberts EO, Awan M, Surendran M, McLean RJ, Reinecke RD, Langmann A, Lindner S, Koch M, Jain S, Woodruff G, Gale RP, Degg C, Droutsas K, Asproudis I, Zubcov AA, Pieh C, Veal CD, Machado Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. Nat Genet. 2006 Nov; 38(11):1242-4. Epub 2006 Oct 01.
    View PubMed
  52. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006 Oct; 68(4):741-6.
    View PubMed
  53. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006 Sep; 176(3):985-90.
    View PubMed
  54. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 1; 107(1):37-45.
    View PubMed
  55. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66(7):3381-5.
    View PubMed
  56. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005 Jul 15; 11(14):5128-39.
    View PubMed
  57. Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell, renal cell carcinoma. Urology. 2005 Jun; 65(6):1090-5.
    View PubMed
  58. Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer. 2004 Jun 15; 100(12):2577-82.
    View PubMed
  59. Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol. 2004 Jan 1; 159(1):42-8.
    View PubMed
  60. Parker AS, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol. 2003 Aug; 170(2 Part 1):420-4.
    View PubMed
  61. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer. 2003 Apr 1; 97(7):1663-71.
    View PubMed
  62. Parker AS, Cerhan JR, Janney CA, Lynch CF, Cantor KP. Smoking cessation and renal cell carcinoma. Ann Epidemiol. 2003 Apr; 13(4):245-51.
    View PubMed
  63. Yang P, Cerhan JR, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Parker AS, Anderson KE, Sellers TA. Adenocarcinoma of the lung is strongly associated with cigarette smoking: Further evidence from a prospective study of women. Am J Epidemiol. 2002 Dec 15; 156(12):1114-22.
    View PubMed
  64. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol. 2002 Aug; 33(8):801-5.
    View PubMed
  65. Parker AS, Cerhan JR, Lynch CF, Ershow AG, Cantor KR. Gender, alcohol consumption, and renal cell carcinoma. Am J Epidemiol. 2002 Mar 1; 155(5):455-62.
    View PubMed
  66. Cerhan JR, Wallace RB, Dick F, Kemp J, Parker AS, Zheng W, Sellers TA, Folsom AR. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):361-8.
    View PubMed
  67. Cerhan JR, Putnam SD, Bianchi GD, Parker AS, Lynch CF, Cantor KP. Tea consumption and risk of cancer of the colon and rectum. Nutr Cancer. 2001; 41(1-2):33-40.
    View PubMed
  68. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000 Aug; 10(6):361-9.
    View PubMed
  69. Parker AS, Cerhan JR, Dick F, Kemp J, Habermann TM, Wallace RB, Sellers TA, Folsom AR. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women. Leuk Lymphoma. 2000 Apr; 37(3-4):341-9.
    View PubMed
  70. Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP. Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol. 2000 Feb 15; 151(4):377-83.
    View PubMed
  71. Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. Epidemiology. 1999 Jul; 10(4):452-5.
    View PubMed
  72. Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, Torner JC, Cantor KP. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev. 1999 Jan; 8(1):53-60.
    View PubMed
  73. Clemmons DR, Busby W Jr., Clarke JB, Parker A, Duan C, Nam TJ. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions Endocrine Journal. 1998; 45(Suppl):S1-8.
    View PubMed
  74. Parker A, Rees C, Clarke J, Busby WH Jr, Clemmons DR. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I Molecular Biology of the Cell. 1998; 9(9):2383-92.
    View PubMed
  75. Arai T, Clarke J, Parker A, Busby W Jr, Nam T, Clemmons DR. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin Journal of Biological Chemistry. 1996; 271(11):6099-106.
    View PubMed
  76. Parker A, Clarke JB, Busby WH Jr, Clemmons DR. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5 Journal of Biological Chemistry. 1996; 271(23):13523-9.
    View PubMed
  77. Parker A, Gockerman A, Busby WH, Clemmons DR. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells Endocrinology. 1995; 136(6):2470-6.
    View PubMed
  78. Gross CR, Savik SK, Ascher NL, Gordon RD, Klintmalm GB, Payne W, Shaw BW, Strasburg K, Parker A, Wiesner RH. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients. Transplant Proc. 1994 Oct; 26(5):2686-90.
    View PubMed
  79. Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes Journal of Biological Chemistry. 1994; 269(32):20388-93.
    View PubMed